<DOC>
	<DOCNO>NCT02063269</DOCNO>
	<brief_summary>Butyrylcholinesterase ( BuChE ) activity increase Alzheimer Disease ( AD ) process ( Lane et al. , 2006 ) . BuChE wild type strong butyrylcholine esterase activity BuChE K variant allele strong activity affect AD brain negatively choline depletion . Rivastigmine unique dual action - acetylcholine esterase inhibition butyrylcholine esterase inhibition . Therefore , rivastigmine low serum butyrylcholine esterase activity delay functional decrease Fluorodeoxyglucose positron emission tomography ( FDG PET ) image AD patient BuChE wild type allele strong BuChE inhibition . It suggest rivastigmine affect brain function differently BuChE genotype AD . Therefore , try find different change serum butyrylcholine esterase activity ELISA functional structural change brain BuChE wild type K-variant type FDG PET MRI pre post image 12 month use rivastigmine . 1 . Primary objective : 1. mean change Standardized Uptake Values ( SUVmean ) PET image 2. mean change serum BuChE activity BuChE wild type K-variant type . 2 . Secondary objective : 1. mean change cortical thickness brain MRI 2. cognitive change Alzheimer 's Disease Assessment Scale-cognitive subscale ( ADAS-cog ) 3. cognitive change Mini-Mental State Exam ( MMSE ) 4. daily function change Alzheimer 's Disease Cooperative Study - Activities Daily Living ( ADCS-ADL ) 5. behavioural change Caregiver-Administered Neuropsychiatric Inventory ( NPI ) 6. disease severity change Clinical Dementia Rating Scale-Sum Boxes ( CDR-SB ) BuChE wild type K-variant type .</brief_summary>
	<brief_title>Brain Changes Rivastigmine According Butyrylcholinesterase Alleles</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Clinical diagnosis Alzheimer 's Disease ( NINCDADRDA MMSE 10 ~26 ) Who n't take Cholinesterase Inhibitor liver within 3 month diagnose disease AD affect brain atrophy accord Brain MRI Diagnosed disease AD affect cognitive function ( i.g . Schizophrenia , Major Depression , Mental Retardation , encephalopathy , etc . ) Did n't suspect drug alcohol addiction within last decade Unable participate study due poor sight hearing Who n't suitable participate accord researcher ' judgement</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>rivastigmine , butyrylcholinesterase , MRI , PET</keyword>
</DOC>